Table of Contents Author Guidelines Submit a Manuscript
Anemia
Volume 2016, Article ID 8494738, 7 pages
http://dx.doi.org/10.1155/2016/8494738
Review Article

Transfusion Thresholds, Quality of Life, and Current Approaches in Myelodysplastic Syndromes

Haematology Department, NHS Lothian, Edinburgh EH4 2XU, UK

Received 28 December 2015; Accepted 4 April 2016

Academic Editor: Aurelio Maggio

Copyright © 2016 Ioannis Koutsavlis. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. A. W. Bracey, R. Radovancevic, S. A. Riggs et al., “Lowering the hemoglobin threshold for transfusion in coronary artery bypass procedures: effect on patient outcome,” Transfusion, vol. 39, no. 10, pp. 1070–1077, 1999. View at Publisher · View at Google Scholar · View at Scopus
  2. L. A. Hajjar, J.-L. Vincent, F. R. B. G. Galas et al., “Transfusion requirements after cardiac surgery: the TRACS randomized controlled trial,” The Journal of the American Medical Association, vol. 304, no. 14, pp. 1559–1567, 2010. View at Publisher · View at Google Scholar · View at Scopus
  3. R. L. Bush, W. C. Pevec, and J. W. Holcroft, “A prospective, randomized trial limiting perioperative red blood cell transfusions in vascular patients,” American Journal of Surgery, vol. 174, no. 2, pp. 143–148, 1997. View at Publisher · View at Google Scholar · View at Scopus
  4. J. L. Carson, M. L. Terrin, F. B. Barton et al., “A pilot randomized trial comparing symptomatic vs. hemoglobin-level-driven red blood cell transfusions following hip fracture,” Transfusion, vol. 38, no. 6, pp. 522–529, 1998. View at Publisher · View at Google Scholar · View at Scopus
  5. J. L. Carson, M. L. Terrin, H. Noveck et al., “Liberal or restrictive transfusion in high-risk patients after hip surgery,” New England Journal of Medicine, vol. 365, no. 26, pp. 2453–2462, 2011. View at Publisher · View at Google Scholar · View at Scopus
  6. N. B. Foss, M. T. Kristensen, P. S. Jensen, H. Palm, M. Krasheninnikoff, and H. Kehlet, “The effects of liberal versus restrictive transfusion thresholds on ambulation after hip fracture surgery,” Transfusion, vol. 49, no. 2, pp. 227–234, 2009. View at Publisher · View at Google Scholar · View at Scopus
  7. C. So-Osman, R. Nelissen, R. Te Slaa, L. Coene, R. Brand, and A. Brand, “A randomized comparison of transfusion triggers in elective orthopaedic surgery using leucocyte-depleted red blood cells,” Vox Sanguinis, vol. 98, no. 1, pp. 56–64, 2010. View at Publisher · View at Google Scholar · View at Scopus
  8. P. C. Hébert, G. Wells, J. Marshall et al., “Transfusion requirements in critical care: a pilot study,” JAMA, vol. 273, no. 18, pp. 1439–1444, 1995. View at Publisher · View at Google Scholar · View at Scopus
  9. L. McIntyre, P. C. Hebert, G. Wells, D. Fergusson, J. Marshall, E. Yetisir et al., “Canadian Critical Care Trials Group. Is a restrictive transfusion strategy safe for resuscitated and critically ill trauma patients?” Journal of Trauma, vol. 57, no. 3, pp. 563–568, 2004. View at Publisher · View at Google Scholar
  10. V. Jairath, B. C. Kahan, A. Gray et al., “Restrictive versus liberal blood transfusion for acute upper gastrointestinal bleeding (TRIGGER): a pragmatic, open-label, cluster randomised feasibility trial,” The Lancet, vol. 386, no. 9989, pp. 137–144, 2015. View at Publisher · View at Google Scholar · View at Scopus
  11. J. L. Carson, P. A. Carless, and P. C. Hebert, “Transfusion thresholds and other strategies for guiding allogeneic red blood cell transfusion,” Cochrane Database of Systematic Reviews, vol. 4, Article ID CD002042, 2012. View at Publisher · View at Google Scholar · View at Scopus
  12. L. B. Holst, M. W. Petersen, N. Haase, A. Perner, and J. Ø. Wetterslev, “Restrictive versus liberal transfusion strategy for red blood cell transfusion: systematic review of randomised trials with meta-analysis and trial sequential analysis,” British Medical Journal, vol. 350, Article ID h1354, 2015. View at Publisher · View at Google Scholar · View at Scopus
  13. A. Ejaz, S. M. Frank, G. Spolverato, Y. Kim, and T. M. Pawlik, “Potential economic impact of using a restrictive transfusion trigger among patients undergoing major abdominal surgery,” JAMA Surgery, vol. 150, no. 7, pp. 625–630, 2015. View at Publisher · View at Google Scholar · View at Scopus
  14. S. L. Goldberg, E. Chen, M. Sasane, C. Paley, A. Guo, and M. Laouri, “Economic impact on US Medicare of a new diagnosis of myelodysplastic syndromes and the incremental costs associated with blood transfusion need,” Transfusion, vol. 52, no. 10, pp. 2131–2138, 2012. View at Publisher · View at Google Scholar · View at Scopus
  15. P. L. Greenberg, L. E. Cosler, S. A. Ferro, and G. H. Lyman, “The costs of drugs used to treat myelodysplastic syndromes following national comprehensive cancer network guidelines,” Journal of the National Comprehensive Cancer Network, vol. 6, no. 9, pp. 942–953, 2008. View at Google Scholar · View at Scopus
  16. T. F. Goss, A. Szende, C. Schaefer et al., “Cost effectiveness of lenalidomide in the treatment of transfusion-dependent myelodysplastic syndromes in the United States,” Cancer Control, vol. 13, supplement, pp. 17–25, 2006. View at Google Scholar · View at Scopus
  17. G. J. Murphy, K. Pike, C. A. Rogers et al., “Liberal or restrictive transfusion after cardiac surgery,” The New England Journal of Medicine, vol. 372, pp. 997–1008, 2015. View at Publisher · View at Google Scholar
  18. J. L. Carson, B. J. Grossman, S. Kleinman et al., “Red blood cell transfusion: a clinical practice guideline from the AABB,” Annals of Internal Medicine, vol. 157, no. 1, pp. 49–58, 2012. View at Publisher · View at Google Scholar · View at Scopus
  19. J. L. Carson and S. Kleinman, “Indications and hemoglobin thresholds for red blood cell transfusion in the adult,” http://www.uptodate.com/contents/indications-and-hemoglobin-thresholds-for-red-blood-cell-transfusion-in-the-adult.
  20. A. Retter, D. Wyncoll, R. Pearse et al., “Guidelines on the management of anaemia and red cell transfusion in adult critically ill patients,” British Journal of Haematology, vol. 160, no. 4, pp. 445–464, 2013. View at Publisher · View at Google Scholar · View at Scopus
  21. S. B. Killick, C. Carter, D. Culligan et al., “Guidelines for the diagnosis and management of adult myelodysplastic syndromes,” British Journal of Haematology, vol. 164, no. 4, pp. 503–525, 2014. View at Publisher · View at Google Scholar
  22. L. Malcovati, E. Hellström-Lindberg, D. Bowen et al., “Diagnosis and treatment of primary myelodysplastic syndromes in adults: recommendations from the European LeukemiaNet,” Blood, vol. 122, no. 17, pp. 2943–2964, 2013. View at Publisher · View at Google Scholar
  23. L. Malcovati, M. G. Della Porta, C. Strupp et al., “Impact of the degree of anemia on the outcome of patients with myelodysplastic syndrome and its integration into the WHO classification-based Prognostic Scoring System (WPSS),” Haematologica, vol. 96, no. 10, pp. 1433–1440, 2011. View at Publisher · View at Google Scholar · View at Scopus
  24. E. N. Oliva, C. Schey, and A. S. Hutchings, “A review of anemia as a cardiovascular risk factor in patients with myelodysplastic syndromes,” American Journal of Blood Research, vol. 1, no. 2, pp. 160–166, 2011. View at Google Scholar
  25. ClinicalTrials.gov, “Red Blood Cell Transfusion Thresholds and QOL in MDS (EnhanceRBC),” ClinicalTrials.gov Identifier: NCT02099669, March 2014.
  26. Red cell transfusion and QoL in myelodysplastic syndromes (REDDS), ISRCTN 26088319.
  27. D. P. Steensma, K. V. Heptinstall, V. M. Johnson et al., “Common troublesome symptoms and their impact on quality of life in patients with myelodysplastic syndromes (MDS): results of a large internet-based survey,” Leukemia Research, vol. 32, no. 5, pp. 691–698, 2008. View at Publisher · View at Google Scholar · View at Scopus
  28. H. Nilsson-Ehle, G. Birgegård, J. Samuelsson et al., “Quality of life, physical function and MRI T2 in elderly low-risk MDS patients treated to a haemoglobin level of 120 g/L with darbepoetin alfa ± filgrastim or erythrocyte transfusions,” European Journal of Haematology, vol. 87, no. 3, pp. 244–252, 2011. View at Publisher · View at Google Scholar · View at Scopus
  29. E. N. Oliva, F. Nobile, G. Alimena et al., “Darbepoetin alfa for the treatment of anemia associated with myelodysplastic syndromes: efficacy and quality of life,” Leukemia & Lymphoma, vol. 51, no. 6, pp. 1007–1014, 2010. View at Publisher · View at Google Scholar · View at Scopus
  30. M. L. Thomas, N. Crisp, and K. Campbell, “The importance of quality of life for patients living with myelodysplastic syndromes,” Clinical Journal of Oncology Nursing, vol. 16, no. 3, pp. 47–57, 2012. View at Publisher · View at Google Scholar · View at Scopus
  31. N. K. Aaronson, S. Ahinedzai, B. Bergman et al., “The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology,” Journal of the National Cancer Institute, vol. 85, no. 5, pp. 365–376, 1993. View at Publisher · View at Google Scholar · View at Scopus
  32. S. B. Yellen, D. F. Cella, K. Webster, C. Blendowski, and E. Kaplan, “Measuring fatigue and other anemia-related symptoms with the Functional Assessment of Cancer Therapy (FACT) measurement system,” Journal of Pain and Symptom Management, vol. 13, no. 2, pp. 63–74, 1997. View at Publisher · View at Google Scholar · View at Scopus
  33. T. R. Mendoza, X. S. Wang, C. S. Cleeland et al., “The rapid assessment of fatigue severity in cancer patients: use of the Brief Fatigue Inventory,” Cancer, vol. 85, no. 5, pp. 1186–1196, 1999. View at Google Scholar
  34. F. Efficace, G. Gaidano, M. Breccia et al., “Prognostic value of self-reported fatigue on overall survival in patients with myelodysplastic syndromes: a multicentre, prospective, observational, cohort study,” The Lancet Oncology, vol. 16, no. 15, pp. 1506–1514, 2015. View at Publisher · View at Google Scholar · View at Scopus
  35. G. A. Abel, R. Klaassen, S. J. Lee et al., “To the editor: Patient-reported outcomes for the myelodysplastic syndromes: a new MDS-specific measure of quality of life,” Blood, vol. 123, no. 3, 2014. View at Publisher · View at Google Scholar · View at Scopus
  36. L. de Swart, A. Smith, P. Fenaux et al., “Transfusion-dependency is the most important prognostic factor for survival in 1000 newly diagnosed MDS patients with low- and intermediate-1 risk MDS in the European LeukemiaNet MDS registry,” in Proceedings of the 53rd Annual Meeting of the American Society of Hematology (ASH '11), San Diego, Calif, USA, November 2011.
  37. PHB Bolton-Maggs (Ed) D Poles et al., on behalf of the Serious Hazards of Transfusion (SHOT) Steering Group. The 2014 Annual SHOT Report, 2015.
  38. A. Saskin, Y. Lin, R. A. Wells et al., “Prophylactic Rh and kell antigen matching significantly decreases rates of alloimmunization in transfusion dependent MDS patients,” Blood, vol. 124, no. 21, p. 4297, 2014. View at Google Scholar
  39. C. Sanz, M. Nomdedeu, M. Belkaid, I. Martinez, B. Nomdedeu, and A. Pereira, “Red blood cell alloimmunization in transfused patients with myelodysplastic syndrome or chronic myelomonocytic leukemia,” Transfusion, vol. 53, no. 4, pp. 710–715, 2013. View at Publisher · View at Google Scholar · View at Scopus
  40. G. A. S. Guelsin, C. Rodrigues, J. E. L. Visentainer et al., “Molecular matching for Rh and K reduces red blood cell alloimmunisation in patients with myelodysplastic syndrome,” Blood Transfusion, vol. 13, no. 1, pp. 53–58, 2015. View at Publisher · View at Google Scholar
  41. L. Malcovati, M. G. Della Porta, C. Pascutto et al., “Prognostic factors and life expectancy in myelodysplastic syndromes classified according to WHO criteria: a basis for clinical decision making,” Journal of Clinical Oncology, vol. 23, no. 30, pp. 7594–7603, 2005. View at Publisher · View at Google Scholar · View at Scopus
  42. M. Takatoku, T. Uchiyama, S. Okamoto et al., “Retrospective nationwide survey of Japanese patients with transfusion-dependent MDS and aplastic anemia highlights the negative impact of iron overload on morbidity/mortality,” European Journal of Haematology, vol. 78, no. 6, pp. 487–494, 2007. View at Publisher · View at Google Scholar · View at Scopus
  43. T. E. Delea, M. Hagiwara, and P. D. Phatak, “Retrospective study of the association between transfusion frequency and potential complications of iron overload in patients with myelodysplastic syndrome and other acquired hematopoietic disorders,” Current Medical Research and Opinion, vol. 25, no. 1, pp. 139–147, 2009. View at Publisher · View at Google Scholar · View at Scopus
  44. C. Rose, S. Brechignac, D. Vassilief et al., “Does iron chelation therapy improve survival in regularly transfused lower risk MDS patients? A multicenter study by the GFM (Groupe Francophone des Myelodysplasies),” Leukemia Research, vol. 34, no. 7, pp. 864–870, 2010. View at Publisher · View at Google Scholar · View at Scopus
  45. P. L. Greenberg, E. Attar, J. M. Bennett et al., “NCCN Clinical Practice Guidelines in Oncology: myelodysplastic syndromes,” Journal of the National Comprehensive Cancer Network, vol. 9, no. 1, pp. 30–56, 2011. View at Google Scholar
  46. J. Neukirchen, F. Fox, A. Kündgen et al., “Improved survival in MDS patients receiving iron chelation therapy—a matched pair analysis of 188 patients from the düsseldorf mds registry,” Leukemia Research, vol. 36, no. 8, pp. 1067–1070, 2012. View at Publisher · View at Google Scholar · View at Scopus
  47. E. Konen, H. Ghoti, O. Goitein et al., “No evidence for myocardial iron overload in multitransfused patients with myelodysplastic syndrome using cardiac magnetic resonance T2* technique,” The American Journal of Hematology, vol. 82, no. 11, pp. 1013–1016, 2007. View at Publisher · View at Google Scholar · View at Scopus
  48. A. A. Di Tucci, G. Matta, S. Deplano et al., “Myocardial iron overload assessment by T2 magnetic resonance imaging in adult transfusion dependent patients with acquired anemias,” Haematologica, vol. 93, no. 9, pp. 1385–1388, 2008. View at Publisher · View at Google Scholar · View at Scopus
  49. J. Chacko, D. J. Pennell, M. A. Tanner et al., “Myocardial iron loading by magnetic resonance imaging T2 in good prognostic myelodysplastic syndrome patients on long-term blood transfusions,” British Journal of Haematology, vol. 138, no. 5, pp. 587–593, 2007. View at Publisher · View at Google Scholar · View at Scopus
  50. G. Caocci, R. Baccoli, A. Ledda, R. Littera, and G. La Nasa, “A mathematical model for the evaluation of amplitude of hemoglobin fluctuations in elderly anemic patients affected by myelodysplastic syndromes: correlation with quality of life and fatigue,” Leukemia Research, vol. 31, no. 2, pp. 249–252, 2007. View at Publisher · View at Google Scholar · View at Scopus
  51. Nova Scotia Provincial Blood Coordinating Program, Guidelines for Home Transfusion, Nova Scotia Provincial Blood Coordinating Program, Halifax, Canada, 2014.
  52. J. Fridey, A. Silvergleid, and J. Tirnauer, Eds., The Path to Safer Home Transfusion: Standardized Procedures, 2013, http://www.uptodate.com/contents/the-path-to-safer-home-transfusion-standardized-procedures#H12.
  53. P. Niscola, A. Tendas, M. Giovannini et al., “Transfusions at home in patients with myelodysplastic syndromes,” Leukemia Research, vol. 36, no. 6, pp. 684–688, 2012. View at Publisher · View at Google Scholar · View at Scopus
  54. E. K. Ritchie, “Blood simple: transfusion at home for patients with MDS,” Leukemia Research, vol. 36, no. 6, pp. 675–676, 2012. View at Publisher · View at Google Scholar · View at Scopus